Vertex Pharmaceuticals’ (VRTX) Buy Rating Reaffirmed at Truist Financial
Truist Financial reiterated their buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $550.00 price target on the pharmaceutical company’s stock, up from their previous price target of $508.00. Several other equities analysts have also commented on […]
More Stories
iShares Premium Money Market ETF Common Class (CMR) To Go Ex-Dividend on September 24th
iShares Premium Money Market ETF Common Class (TSE:CMR – Get Free Report) announced a monthly dividend on Tuesday, September 24th,...
Torture ‘a common and acceptable practice’ in Ukraine war, UN investigators say
Russian authorities are using torture “with a sense of impunity” in the ongoing war in Ukraine, the UN Human Rights...
Whirlpool Co. (NYSE:WHR) Receives Average Rating of “Reduce” from Analysts
Shares of Whirlpool Co. (NYSE:WHR – Get Free Report) have been given an average recommendation of “Reduce” by the five...
Cervical Cancer: Symptoms, Causes, Treatments, and Natural Approaches
By Mercura Wang Cervical cancer originates in the cells of the cervix, the lower part of the uterus (womb), where...
Get Out of Debt Now
By Jeffrey A. Tucker Long ago, when I was in college, there was a long line of credit card companies...
Trump Suspect Ryan Routh Left Note: ‘This Was an Assassination Attempt’
By Jack Phillips A court document submitted by federal prosecutors on Monday showed that Ryan Routh, the suspect in the...